Consequences of glycan truncation on Fc structural integrity

mAbs

Volumn 5, Issue 6, 2013, Pages 904-916

  Buck, Patrick M ^a   Kumar, Sandeep ^a   Singh, Satish K ^a  

^a PFIZER INC   (United States)

Author keywords

Fc; Glycans; Glycosylation; Molecular dynamics; Monoclonal antibodies; Oligosaccharides; Stability

Indexed keywords

GLYCAN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; POLYSACCHARIDE; WATER;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATION; CRYSTAL STRUCTURE; DEGLYCOSYLATION; GLYCOSYLATION; MOLECULAR DYNAMICS; PROTEIN QUATERNARY STRUCTURE; PROTEIN STABILITY; THERMOSTABILITY; BIOLOGICAL MODEL; CHEMISTRY; HEAT; HUMAN; METABOLISM; PROTEIN DATABASE; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; GLYCOSYLATION; HOT TEMPERATURE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION; POLYSACCHARIDES; WATER;

EID: 84889811290     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.26453     Document Type: Article

References (58)

1. Aggarwal S. Targeted cancer therapies. Nat Rev Drug Discov 2010; 9:427-8; PMID:20514063; http://dx.doi.org/10.1038/nrd3186
2. Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21:1-7; PMID:17263584; http://dx.doi.org/10.2165/00063030-200721010-00001
3. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526:159-66; PMID:22465822; http://dx.doi.org/10.1016/ j.abb.2012.03.021
4. Kabat EA, Te Wu T, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Darby (PA); Diane Publishing; 1992.
5. Raju S. Glycosylation variations with expression systems. Westborough (MA); BioProcess International; 2003:44-53.
6. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10:477-86; PMID:10764836; http://dx.doi.org/10.1093/glycob/10.5.477
7. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
8. Raju TS. Terminal sugars of Fc glycans influence anti-body effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007
9. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311-8; PMID:8643100; http://dx.doi.org/10.1016/0161-5890(95) 00118-2
10. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w
11. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 2007; 368:767-79; PMID:17368483; http://dx.doi.org/10.1016/j.jmb.2007.02.034
12. Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 2013; PMID:23851282; http://dx.doi.org/10.1016/j.ymeth.2013.06.036
13. Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs 2013; 5:219-28; PMID:23406897; http://dx.doi.org/10.4161/mabs.23532
14. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:419-25; PMID:22699226; http://dx.doi.org/10. 4161/mabs.20996
15. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011; 3:415-6; PMID:21785279; http://dx.doi.org/10.4161/mabs.3.5.17334
16. Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013; 5; PMID:23924801; http://dx.doi.org/10.4161/mabs.25423
17. Burnina I, Hoyt E, Lynaugh H, Li H, Gong B. A cost-effective plate-based sample preparation for antibody N-glycan analysis. J Chromatogr A 2013; 1307:201-6; PMID:23932029; http://dx.doi.org/10.1016/j.chroma.2013.07.104
18. Stöckmann H, Adamczyk B, Hayes J, Rudd PM. Automated, high-throughput IgG-antibody glycoprofiling platform. Anal Chem 2013; PMID:23919734; http://dx.doi.org/10.1021/ac402068r
19. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37:697-706; PMID:11275255; http://dx.doi.org/10. 1016/S0161-5890(00)00105-X
20. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011; 3:568-76; PMID:22123061; http://dx.doi.org/10.4161/mabs.3.6.17922
21. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 2012; 287:1381-96; PMID:22084250; http://dx.doi.org/10.1074/jbc.M111.297697
22. Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009; 98:1223-45; PMID:18661536; http://dx.doi.org/10.1002/jps.21504
23. Rhodes G. Crystallography made crystal clear: a guide for users of macromolecular models. Philadelphia (PA); Elsevier Academic Press; 2010.
24. Houde D, Arndt J, Domeier W, Berkowitz S, Engen Jr. Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry. Anal Chem 2009; 81:5966; PMID:19606834; http://dx.doi.org/10. 1021/ac9009287
25. Caflisch A. Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol 2006; 10:437-44; PMID:16880001; http://dx.doi.org/10.1016/j.cbpa.2006.07.009
26. Chaudhri A, Zarraga IE, Yadav S, Patapoff TW, Shire SJ, Voth GA. The role of amino acid sequence in the self-association of therapeutic monoclonal antibodies: insights from coarse-grained modeling. J Phys Chem B 2013; 117:1269-79; PMID:23316912; http://dx.doi.org/10.1021/jp3108396
27. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B 2010; 114:6614-24; PMID:20411962; http://dx.doi.org/10.1021/jp911706q
28. Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, Trout BL. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS One 2009; 4:e8425; PMID:20037630; http://dx.doi.org/10.1371/journal.pone.0008425
29. Wu C, Shea JE. Coarse-grained models for protein aggregation. Curr Opin Struct Biol 2011; 21:209-20; PMID:21371882; http://dx.doi.org/10.1016/j.sbi. 2011.02.002
30. Wang X, Kumar S, Buck PM, Singh SK. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 2013; 81:443-60; PMID:23065923; http://dx.doi.org/10.1002/prot.24202
31. Buck PM, Kumar S, Singh SK. Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics. Protein Eng Des Sel 2013; 26:195-205; PMID:23188804; http://dx.doi.org/10.1093/ protein/gzs099
32. Wang X, Kumar S, Singh SK. Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations. Pharm Res 2011; 28:3128-44; PMID:21671135; http://dx.doi.org/10.1007/s11095-011-0503-9
33. Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta 2006; 1760:693-700; PMID:16343775; http://dx.doi.org/10.1016/j.bbagen.2005.10. 002
34. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20:2361-70; PMID:7236608; http://dx.doi.org/10.1021/bi00512a001
35. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0
36. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; http://dx.doi.org/10.1038/nri2155
37. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30(Suppl 1):S9-14; PMID:20480216; http://dx.doi.org/10.1007/s10875-010-9405-6
38. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6; PMID:18420934; http://dx.doi.org/10.1126/science. 1154315
39. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203:789-97; PMID:16520389; http://dx.doi.org/10.1084/ jem.20051900
40. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A 2013; 110:9868-72; PMID:23697368; http://dx.doi.org/10.1073/pnas.1307864110
41. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36:1370-80; PMID:9063885; http://dx.doi.org/10.1021/bi9621472
42. Yamaguchi Y, Kato K, Shindo M, Aoki S, Furusho K, Koga K, Takahashi N, Arata Y, Shimada I. Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. J Biomol NMR 1998; 12:385-94; PMID:9835046; http://dx.doi.org/10.1023/A:1008392229694
43. Barb AW, Meng L, Gao Z, Johnson RW, Moremen KW, Prestegard JH. NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 2012; 51:4618-26; PMID:22574931; http://dx.doi.org/10.1021/ bi300319q
44. Barb AW, Prestegard JH. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol 2011; 7:147-53; PMID:21258329; http://dx.doi.org/10.1038/nchembio.511
45. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/35018508
46. Deisenhofer J, Colman PM, Huber R, Haupt H, Schwick G. Crystallographic structural studies of a human Fc-fragment. I. An electron-density map at 4 A resolution and a partial model. Hoppe Seylers Z Physiol Chem 1976; 357:435-45; PMID:955567; http://dx.doi.org/10.1515/bchm2.1976.357.1.435
47. Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 1976; 264:415-20; PMID:1004567; http://dx.doi.org/10.1038/264415a0
48. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001; 293:1155-9; PMID:11498595; http://dx.doi.org/10.1126/science.1061692
49. Perez D, Uberuaga BP, Voter AF. Accelerated Molecular Dynamics Methods. Hierarchical Methods for Dynamics in Complex Molecular Systems 2012; 10:329
50. Caflisch A, Karplus M. Molecular dynamics simulation of protein denaturation: solvation of the hydrophobic cores and secondary structure of barnase. Proc Natl Acad Sci U S A 1994; 91:1746-50; PMID:8127876; http://dx.doi.org/10.1073/pnas.91.5.1746
51. Caflisch A, Karplus M. Acid and thermal denaturation of barnase investigated by molecular dynamics simulations. J Mol Biol 1995; 252:672-708; PMID:7563082; http://dx.doi.org/10.1006/jmbi.1995.0528
52. Li A, Daggett V. Identification and characterization of the unfolding transition state of chymotrypsin inhibitor 2 by molecular dynamics simulations. J Mol Biol 1996; 257:412-29; PMID:8609633; http://dx.doi.org/10.1006/jmbi.1996. 0172
53. Molecular Operating Environment (MOE). Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2011.
54. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26:1781-802; PMID:16222654; http://dx.doi.org/10.1002/jcc. 20289
55. Wang J, Cieplak P, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem 2000; 21:1049-74; http://dx.doi.org/10. 1002/1096-987X(200009)21:12〈1049::AID-JCC3〉3.0.CO;2-F
56. Kirschner KN, Yongye AB, Tschampel SM, González-Outeiriño J, Daniels CR, Foley BL, Woods RJ. GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem 2008; 29:622-55; PMID:17849372; http://dx.doi.org/10.1002/jcc.20820
57. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-8, 27-8; PMID:8744570; http://dx.doi.org/10.1016/0263-7855(96) 00018-5
58. Cross S, Kuttel MM, Stone JE, Gain JE. Visualisation of cyclic and multi-branched molecules with VMD. J Mol Graph Model 2009; 28:131-9; PMID:19473861; http://dx.doi.org/10.1016/j.jmgm.2009.04.010